A few days ago, an article was published in the journal Pediatrics on neonatal morbidity observed in children exposed to antidepressants. Although this article is likely to find its way into the headlines, it is important to note that the information presented here is nothing new. Similar to previous studies, the Pediatrics study reveals higher […]
Tag Archives | neonatal outcomes
We are seeing an increasing number of women in our clinic who are using marijuana on a regular basis — recreationally and medically prescribed — to help them manage various psychiatric symptoms, including depression and anxiety. This is no surprise given that many states have or are now moving forward with the legalization of medical […]
The use of opioid drugs in women of childbearing age has become a pressing public health concern. It is clear that opiate use during pregnancy puts the mother and child at risk; opiate use during pregnancy has been associated with increased risk for oral clefts, neural tube defects, gastroschisis, congenital heart defects, and ophthalmic problems. […]
Given the number of younger women using atypical antipsychotic medications, we need more accurate data regarding the reproductive safety of these medications. To better understand the link between antipsychotic medication and medical conditions associated with pregnancy, including gestational diabetes and hypertension, researchers compared pregnancy outcomes in 1,021 pregnant women taking antipsychotic medication to outcomes in […]
Second-generation or “atypical” antipsychotics, such as olanzapine (Zyprexa), aripiprazole (Abilify), and risperidone (Risperdal), are used far more frequently than are the first-generation or “typical” antipsychotics, such as haloperidol (Haldol). This is largely because the newer agents are associated with fewer side effects and, as a result, have been used for a wider spectrum of illnesses, […]
You can find a more recent post on this topic here: Venlafaxine and Duloxetine: Pooled Analysis Shows No Increase in Risk of Malformations We receive a fair number of questions on the use of duloxetine during pregnancy. Duloxetine (sold in the United Sates under the brand name of Cymbalta) is a serotonin-norepinephrine reuptake inhibitor (SNRI) […]
Posttraumatic stress disorder (PTSD) is relatively common among pregnant and postpartum women. The lifetime prevalence of PTSD for women is about 10%. PTSD is most prevalent among women of childbearing age and PTSD symptoms are common during pregnancy. Earlier this year, we reported on a study which observed that women with a diagnosis of PTSD had an increased risk of preterm birth. The risk was particularly high in those women with diagnoses of both PTSD and a major depressive episode; these women had a 4-fold increased risk of preterm birth.
The PPHN story has been a bit of a rollercoaster. Just to review…
Since their introduction in the 1990s, atypical (second-generation) antipsychotics have replaced typical (first generation) antipsychotics as the first-line treatment for schizophrenia and related psychotic disorders. These drugs are widely used by reproductive age women across many other disease states including bipolar disorder, major depression and anxiety disorders as either primary or adjunctive treatments.
Atypical antipsychotic medications are commonly used for the treatment of schizophrenia and bipolar disorder. Despite the increasing use of these medications in women of child-bearing age, there is still relatively little data regarding the reproductive safety and long-term neurodevelopmental effects of these medications. A recent study assessed the development of 76 infants with fetal exposure to atypical antipsychotics.